Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
and HPV testing every 5 years. See the Clinical Considerations for
discussion of cytology method, HPV testing, and screening interval
(A recommendation).
The USPSTF recommends against screening for cervical cancer in
women younger than age 21 years (D recommendation).
The USPSTF recommends against screening for cervical cancer in
women older than age 65 years who have had adequate prior
screening and are not otherwise at high risk for cervical cancer. See
the Clinical Considerations for discussion of adequacy of prior
screening and risk factors (D recommendation).
The USPSTF recommends against screening for cervical cancer in
women who have had a hysterectomy with removal of the cervix
and who do not have a history of a high-grade precancerous lesion
(cervical intraepithelial neoplasia grade 2 or 3) or cervical cancer (D
recommendation).
The USPSTF recommends against screening for cervical cancer
with HPV testing, alone or in combination with cytology, in women
younger than age 30 years (D recommendation).
Ann Intern Med. 2012;156:880-891.
www.annals.org
For author affiliation, see end of text.
* For a list of the members of the USPSTF, see the Appendix (available at
www.annals.org).
This article was published at www.annals.org on 15 March 2012.
SUMMARY
See also:
Print
Editorial comment. . . . . . . . . . . . . . . . . . . . . . . . . . 896
Summary for Patients. . . . . . . . . . . . . . . . . . . . . . . I-44
Web-Only
Appendix
CME quiz (preview on page I-23)
Conversion of graphics into slides
OF
RECOMMENDATIONS
AND
EVIDENCE
www.annals.org
screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. See the Clinical
Considerations for discussion of cytology method, HPV
testing, and screening interval (A recommendation).
The USPSTF recommends against screening for cervical cancer in women younger than age 21 years (D
recommendation).
The USPSTF recommends against screening for cervical
cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer. See the Clinical Considerations for discussion of adequacy of prior screening and risk factors (D recommendation).
The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with
removal of the cervix and who do not have a history of
a high-grade precancerous lesion (cervical intraepithelial
neoplasia [CIN] grade 2 or 3) or cervical cancer (D
recommendation).
The USPSTF recommends against screening for cervical
cancer with HPV testing, alone or in combination with
cytology, in women younger than age 30 years (D
recommendation).
See the Figure for a summary of the recommendations
and suggestions for clinical practice.
Table 1 describes the USPSTF grades, and Table 2
describes the USPSTF classification of levels of certainty
about net benefit.
RATIONALE
Importance
The age-adjusted annual incidence rate of cervical cancer is 6.6 cases per 100 000 women, according to data
from 2008 (13). An estimated 12 200 new cases of cervical cancer and 4210 deaths occurred in the United States
in 2010 (1). Cervical cancer deaths in the United States
have decreased dramatically since the implementation of
widespread cervical cancer screening. Most cases of cervical
cancer occur in women who have not been appropriately
screened (2, 3). Strategies that aim to ensure that all
women are screened at the appropriate interval and receive
adequate follow-up are most likely to be successful in
further reducing cervical cancer incidence and mortality
in the United States.
Clinical Guideline
Detection
The harms of treatment include risks from the treatment procedure itself and the potential downstream
consequences of treatment. Summary evidence from observational studies indicates that some treatments for
precancerous lesions (such as cold-knife conization and
loop excision) are associated with adverse pregnancy outcomes, such as preterm delivery, that can lead to low
birthweight in infants and perinatal death (2). Evidence is
convincing that many precancerous cervical lesions will re19 June 2012 Annals of Internal Medicine Volume 156 Number 12 881
Clinical Guideline
Figure. Screening for cervical cancer: clinical summary of U.S. Preventive Services Task Force recommendation.
Recommendation
Women Aged 21
to 65 Years
Women Aged 30
to 65 Years
Women
Younger
Than Age
21 Years
Do not screen
Do not screen
Women After
Hysterectomy With
Removal of the Cervix
With No History of
High-Grade Precancer or
Cervical Cancer
Do not screen
Grade: D
Grade: D
Grade: D
Women Younger
Than Age 30 Years
Grade: A
Risk Assessment
Screening Tests
and Interval
Timing of
Screening
Interventions
Balance of Benefits
and Harms
Other Relevant
USPSTF
Recommendations
HPV infection is associated with nearly all cases of cervical cancer. Other factors that increase a woman's risk for cervical cancer
include HIV infection, a compromised immune system, in utero exposure to diethylstilbestrol, and previous treatment
of a high-grade precancerous lesion or cervical cancer.
Screening women aged 21 to 65 years every 3 years with cytology provides a reasonable balance between benefits and harms.
Screening with cytology more often than every 3 years confers little additional benefit, with large increases in harms.
HPV testing combined with cytology (co-testing) every 5 years in women aged 30 to 65 years offers a comparable balance of benefits and
harms, and is therefore a reasonable alternative for women in this age group who would prefer to extend the screening interval.
Screening women younger than age 21 years, regardless of sexual history, leads to more harms than benefits.
Clinicians and patients should base the decision to end screening on whether the patient meets the criteria for adequate
prior testing and appropriate follow-up, per established guidelines.
Screening aims to identify high-grade precancerous cervical lesions to prevent development of cervical cancer
and early-stage asymptomatic invasive cervical cancer.
High-grade lesions may be treated with ablative and excisional therapies, including cryotherapy, laser ablation,
loop excision, and cold-knife conization.
Early-stage cervical cancer may be treated with surgery (hysterectomy) or chemoradiation.
The benefits of
screening with
cytology every 3
years substantially
outweigh the harms.
The benefits of
screening with
co-testing
(cytology/HPV
testing) every 5 years
outweigh the harms.
The harms of
screening earlier than
age 21 years
outweigh the
benefits.
The benefits of
screening after
age 65 years do
not outweigh the
potential harms.
The harms of
screening after
hysterectomy
outweigh the
benefits.
The USPSTF has made recommendations on screening for breast cancer and ovarian cancer, as well as genetic risk assessment and BRCA
mutation testing for breast and ovarian cancer susceptibility. These recommendations are available at
www.uspreventiveservicestaskforce.org.
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents,
please go to www.uspreventiveservicestaskforce.org.
Pap Papanicolaou.
gress and that other lesions are so indolent and slowgrowing that they will not become clinically important
over a womans lifetime; identification and treatment of
these lesions constitute overdiagnosis. It is difficult to estimate the precise magnitude of overdiagnosis associated
with any screening or treatment strategy, but it is of concern because it confers no benefit and leads to unnecessary
surveillance, diagnostic tests, and treatments with the associated harms.
882 19 June 2012 Annals of Internal Medicine Volume 156 Number 12
Clinical Guideline
Table 1. What the USPSTF Grades Mean and Suggestions for Practice
Grade
Definition
The USPSTF recommends the service. There is high certainty that the net benefit
is substantial.
The USPSTF recommends the service. There is high certainty that the net benefit
is moderate or there is moderate certainty that the net benefit is moderate to
substantial.
Note: The following statement is undergoing revision.
Clinicians may provide this service to selected patients depending on individual
circumstances. However, for most individuals without signs or symptoms there
is likely to be only a small benefit from this service.
The USPSTF recommends against the service. There is moderate or high
certainty that the service has no net benefit or that the harms outweigh the
benefits.
The USPSTF concludes that the current evidence is insufficient to assess the
balance of benefits and harms of the service. Evidence is lacking, of poor
quality, or conflicting, and the balance of benefits and harms cannot be
determined.
I Statement
USPSTF Assessment
Description
High
Moderate
There is adequate evidence that screening after hysterectomy among women who do not have a history of a
high-grade precancerous lesion or cervical cancer is associated with harms.
Low
* The USPSTF defines certainty as likelihood that the USPSTF assessment of the
net benefit of a preventive service is correct. The net benefit is defined as benefit
minus harm of the preventive service as implemented in a general, primary care
population. The USPSTF assigns a certainty level based on the nature of the
overall evidence available to assess the net benefit of a preventive service.
19 June 2012 Annals of Internal Medicine Volume 156 Number 12 883
Clinical Guideline
CLINICAL CONSIDERATIONS
Patient Population Under Consideration
Clinical Guideline
OTHER CONSIDERATIONS
Research Needs and Gaps
Clinical Guideline
DISCUSSION
Burden of Disease
Evidence suggests that there are no clinically meaningful differences in accuracy between liquid-based cytology
and conventional cytology. One large, good-quality randomized trial (10) and one large, fair-quality randomized
trial (11) of more than 130 000 women compared the 2
screening methods and found no difference in detection of
CIN2 or CIN3 at any cytologic threshold of positivity.
HPV Testing Compared With Cytology
Clinical Guideline
Clinical Guideline
Clinical Guideline
The natural history of cervical cancer has been wellstudied. Human papillomavirus infection of the cervix is
generally transient, but when the infection is not cleared by
an appropriate immune response and the HPV is of an
oncogenic type, the infection can result in incorporation of
HPV gene sequences into the host genome, which can lead
to precancerous lesions. The long preclinical phase from
infection to development of precancerous lesions and cervical cancer allows for the opportunity to efficiently screen
for and identify precancerous lesions and treat them,
thereby reducing the incidence of cervical cancer incidence
and mortality.
www.annals.org
Clinical Guideline
UPDATE
OF
This recommendation updates the 2003 USPSTF recommendation (44) on screening for cervical cancer. It differs
from the previous recommendation in that it recommends
cytology screening every 3 years among women aged 21 to 65
years. In addition, this recommendation includes more guidance on the appropriate age ranges and frequency of screening, including a new recommendation that women younger
than age 21 years not be screened because the evidence shows
no net benefit. The previous recommendation suggested that
most of the benefit of screening could be obtained by beginning screening within 3 years of onset of sexual activity or age
21 years (whichever comes first) and screening at least every 3
years. This recommendation reaffirms the previous recommendations against screening in adequately screened women
older than age 65 years and in women who have had a total
hysterectomy with removal of the cervix. The current recommendation includes new evidence on the comparative test performance of liquid-based versus conventional cytology that
indicates no substantial difference in test performance (that is,
relative detection or absolute sensitivity or specificity) for detection of CIN2/CIN3. It also includes more guidance
on the appropriate use of HPV testing in cervical cancer
screening, including a new recommendation that women
younger than aged 30 years not be screened with HPV testing.
The USPSTF found new evidence that addressed the gaps
identified in the previous recommendation and allowed the
USPSTF to recommend HPV testing combined with cytology as an acceptable screening strategy for women aged 30 to
65 years who prefer to lengthen their screening interval beyond 3 years.
RECOMMENDATIONS
OF
OTHERS
The U.S. Congress mandates that the Agency for Healthcare Research
and Quality support the operations of the USPSTF.
Potential Conflicts of Interest: Disclosure forms from USPSTF mem-
References
1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W,
et al, eds. SEER Cancer Statistics Review, 19752008. Bethesda, MD: National
Cancer Institute; 2011. Accessed at http://seer.cancer.gov/csr/1975_2008/ on 11
October 2011.
2. Vesco KK, Whitlock EP, Eder M, Lin J, Burda BU, Senger CA, et al.
Screening for cervical cancer: a systematic evidence review for the U.S. Preventive
Services Task Force. Evidence Synthesis No. 86. AHRQ Publication No. 1105156-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
3. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. Risk
factors and other epidemiologic considerations for cervical cancer screening: a
narrative review for the U.S. Preventive Services Task Force. Ann Intern Med.
2011;155:698-705, W216. [PMID: 22006929]
4. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for cervical
cancer: a decision analysis for the U.S. Preventive Services Task Force. AHRQ
Publication No. 11-05157-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
5. Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, et al.
Human papillomavirus infection and cervical cytology in women screened for
cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148:493500. [PMID: 18378945]
6. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Five-year
experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113:595-600. [PMID: 19300322]
7. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J,
et al. American Cancer Society, American Society for Colposcopy and Cervical
Pathology, and American Society for Clinical Pathology screening guidelines for
the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012.
[PMID: 22422631]
8. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al;
HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused
by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-14. [PMID: 19586656]
9. Centers for Disease Control and Prevention, National Breast and Cervical
Cancer Early Detection Program. Screening program summaries: national
aggregate. Accessed at www.cdc.gov/cancer/nbccedp/data/summaries/national
_aggregate.htm on 11 October 2011.
10. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C,
et al. Accuracy of liquid based versus conventional cytology: overall results of new
www.annals.org
www.annals.org
Clinical Guideline
www.annals.org